1. Home
  2. PRTC vs JELD Comparison

PRTC vs JELD Comparison

Compare PRTC & JELD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • PRTC
  • JELD
  • Stock Information
  • Founded
  • PRTC 2015
  • JELD 1960
  • Country
  • PRTC United States
  • JELD United States
  • Employees
  • PRTC N/A
  • JELD N/A
  • Industry
  • PRTC Biotechnology: Pharmaceutical Preparations
  • JELD Forest Products
  • Sector
  • PRTC Health Care
  • JELD Basic Materials
  • Exchange
  • PRTC Nasdaq
  • JELD Nasdaq
  • Market Cap
  • PRTC 413.5M
  • JELD 383.8M
  • IPO Year
  • PRTC N/A
  • JELD 2017
  • Fundamental
  • Price
  • PRTC $18.01
  • JELD $5.78
  • Analyst Decision
  • PRTC Buy
  • JELD Hold
  • Analyst Count
  • PRTC 1
  • JELD 8
  • Target Price
  • PRTC $45.00
  • JELD $7.50
  • AVG Volume (30 Days)
  • PRTC 2.8K
  • JELD 1.5M
  • Earning Date
  • PRTC 08-27-2025
  • JELD 08-05-2025
  • Dividend Yield
  • PRTC N/A
  • JELD N/A
  • EPS Growth
  • PRTC N/A
  • JELD N/A
  • EPS
  • PRTC 0.21
  • JELD N/A
  • Revenue
  • PRTC $4,828,000.00
  • JELD $3,430,185,000.00
  • Revenue This Year
  • PRTC N/A
  • JELD N/A
  • Revenue Next Year
  • PRTC N/A
  • JELD $3.46
  • P/E Ratio
  • PRTC $8.19
  • JELD N/A
  • Revenue Growth
  • PRTC 44.98
  • JELD N/A
  • 52 Week Low
  • PRTC $13.30
  • JELD $3.27
  • 52 Week High
  • PRTC $25.00
  • JELD $16.43
  • Technical
  • Relative Strength Index (RSI)
  • PRTC 49.08
  • JELD 64.97
  • Support Level
  • PRTC $15.21
  • JELD $5.09
  • Resistance Level
  • PRTC $18.20
  • JELD $6.07
  • Average True Range (ATR)
  • PRTC 0.54
  • JELD 0.33
  • MACD
  • PRTC -0.12
  • JELD 0.09
  • Stochastic Oscillator
  • PRTC 71.92
  • JELD 83.09

About PRTC PureTech Health plc

PureTech Health PLC, together with its subsidiaries, is a clinical-stage biopharma company developing medicines to modulate the adaptive human system. The company is focused on developing and commercializing differentiated medicines for devastating diseases, including inflammatory, immunological conditions, intractable cancers, lymphatic & gastrointestinal diseases, and neurological and neuropsychological disorders, among others. Its drug development pipeline consists of Deupirfenidone (LYT-100), for the potential treatment of idiopathic pulmonary fibrosis (IPF), LYT-200, SPT-300, an oral drug for depressive disorder, SPT-320, and others. The company's operating segments include Parent Companies & Other, which derives key revenue, Wholly-Owned Programs, and Controlled Founded Entities.

About JELD JELD-WEN Holding Inc.

JELD-WEN Holding Inc is engaged in door and window manufacturing. The company designs, produces, and distributes interior and exterior building products, offering a selection of doors, windows, walls, and related products. The products are used in the new construction of residential single and multi-family homes and non-residential buildings. The firm's operating segments are North America, Europe, and Australasia. It generates a majority of its revenue from North America.

Share on Social Networks: